Exploring the Application of Target Trial Emulation in Vaccine Evaluation: Scoping Review and Recommendations for Future Studies

Toshiaki Komura[1], Miwa Watanabe[1], Kayoko Shioda[2, 3]

Author affiliations:

1. Department of Epidemiology, School of Public Health, Boston University, Boston, MA, USA
2. Department of Global Health, School of Public Health, Boston University, Boston, MA, USA
3. Center on Emerging Infectious Diseases, Boston University, Boston, MA, USA

Corresponding author:

Kayoko Shioda, PhD, DVM, MPH
Department of Global Health, School of Public Health, Boston University, Boston, MA, USA
Center on Emerging Infectious Diseases, Boston University, Boston, MA, USA
Address: 801 Massachusetts Avenue, Boston, MA, USA, 02118
Phone: (617) 358-2422
E-mail address: kshioda@bu.edu

ABSTRACT

Background: Target trial emulation has gained popularity in evaluating treatments and health interventions. Its application to infectious disease outcomes requires careful consideration, as infectious disease transmission violates the assumption of no interference. We conducted a scoping review to understand how target trial emulation approaches have been applied to vaccine evaluation.

Methods: We conducted a systematic search of literature published in PubMed, Embase, and Web of Science until May 2024, using keywords related to target trial emulation, infectious diseases, and vaccines. Three independent reviewers screened titles and abstracts for relevance. Full-text articles meeting inclusion criteria were further assessed for eligibility.

Results: Our search identified 236 studies. Of these, 30 original research studies employed target trial emulation approaches to evaluate vaccines, predominantly published from 2022 to 2024. Most studies (n=28, 93%) were conducted in high-income countries. The majority (n=27, 90%) evaluated the effect of COVID-19 vaccines, with one study each evaluating influenza, MPOX, and rotavirus vaccines. Nationwide healthcare databases were used in 17 studies (57%). Twenty-one studies (70%) conducted analysis among adults aged ≥18 years, while four studies (13%) focused on children <18 years. Most studies did not define the type of vaccine effect they evaluated (e.g., direct, indirect, total, or overall effect), and none incorporated interference in vaccine evaluation.

Discussion: Our review highlights the increasing popularity of target trial emulation in vaccine evaluation following the COVID-19 pandemic. Further discussions are needed to understand how interference can be addressed within this framework.

INTRODUCTION

Target trial emulation (TTE) is a causal inference framework that allows us to emulate a hypothetical target trial using observational data. TTE has become a popular research method to evaluate treatment and health interventions due to its practical and methodological advantages, serving as an important alternative to randomized controlled trials (RCTs).[1] While head-to-head RCTs are widely regarded as the gold standard for intervention evaluation, operational and ethical challenges often hinder the randomization of participants in RCTs. Even when RCTs are feasible, they are generally restricted to small sample sizes and short follow-up periods, making it difficult to detect rare or long-term outcomes.[2] RCTs also face constraints in comparing a large number of different protocols with various doses and treatment schedules due to resource limitations. Additionally, RCTs are primarily conducted in urban settings in high-income countries with selected population groups,[3,4] leaving underrepresented groups reliant on findings from contexts that may not align with their own.[5,6]

Observational studies could become useful to address these challenges posed by RCTs, especially when leveraging existing surveillance systems or large-scale health data.[7] Existing surveillance systems can provide affordable and readily available data for intervention evaluation, helping us overcome operational and ethical challenges with RCTs. If surveillance systems cover the whole nation for a long time period, they could provide important information on short- and long-term outcomes of various diseases across demographic characteristics and geographic locations. However, as widely discussed, observational studies come with their own set of analytic challenges, including selection bias, immortal time bias, and confounding.[7–12]

TTE is a promising tool to harness the benefits of observational data while mitigating their analytic challenges.[1] TTE facilitates causal inference using observational data, by mimicking a hypothetical target trial. By clearly specifying "time-zero" for treatment and control groups, TTE aims to effectively remove selection bias and immortal time bias. With the blurred lines between methodological advances in RCTs and observational studies, TTE has garnered attention as a convenient design for evaluating interventions.[13]

While TTE has promising applications, it requires careful attention when used in the context of infectious diseases, where outcomes often do not satisfy the fundamental assumption of causal inference—no interference.[14,15] Infectious diseases, which spread from infected individuals to susceptible individuals, challenge the assumption that the treatment of one person does not affect another person.[16,17] This concern becomes particularly important when evaluating the effect of vaccines, because vaccination reduces population-level transmission, subsequently lowering the risk of infection among both vaccinated and unvaccinated individuals. In fact, vaccine evaluation has well-established guidelines categorizing vaccine effects into the following four types:[18,19]

1) *direct effect*, which is the difference between the outcome in the vaccinated individual and what the outcome would have been without vaccination in the same person;

2) *indirect effect*, which is the difference in the outcome in the unvaccinated individual in a population with a vaccination program and what the outcome would have been in the unvaccinated individual in a population without a vaccination program;

3) *total effect,* which is the difference between the outcome in the vaccinated individual in a population with a vaccination program and what the outcome would have been in the unvaccinated individual in a comparable population without a vaccination program; and

4) *overall effect,* which is the difference in the outcome in an average vaccinated individual in a population with a vaccination program compared with the outcome of an unvaccinated individual in a comparable population without a vaccination program.

In light of these considerations, we explored how the TTE framework has been applied to vaccine evaluation. This scoping review investigated the recent trends in the use of TTE for assessing vaccine effectiveness and safety. We summarized the target populations, data sources, vaccine products, comparators, and clinical outcomes. Additionally, we examined specific TTE and statistical methods used in each study, and investigated how studies defined specific types of vaccine effects within the TTE framework. Finally, we evaluated whether and how studies addressed the dependent nature of infectious diseases. Based on findings from the scoping review, we highlighted methodological gaps and provided recommendations for future studies using TTE in the field of vaccine evaluation.

METHODS

Search strategy

We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) extension for a scoping review checklist to design this scoping review.[20] The protocol of this scoping review was registered with the Open Science Framework Registries on January 29, 2024.[21] Studies were extracted from three databases: PubMed, Embase, and Web of Science. The databases were searched from January 1, 2012, following the protocol of a previous systematic review,[22] to May 21, 2024. Studies published in English were included. The search term included keywords related to vaccine evaluation and target trial emulation and was determined through group consensus (**Supplementary Table 1**). As TTE approaches are relatively new, especially in the field of vaccine evaluation, studies may have not explicitly stated that TTE approaches were used. The authors aimed to identify these studies by going through the literature and citations of identified studies.

Eligibility Criteria

Three independent reviewers (TK, MW, and KS) screened titles and abstracts based on the following inclusion criteria: 1) original research articles, 2) primary objectives that include the evaluation of vaccines, 3) study designs that adhere to a target trial emulation framework, and 4) peer-reviewed articles published in scientific journals.

Data Extraction

To examine study characteristics, we extracted the following information: authors, year of publication, countries of origin, target populations, data sources, treatments (i.e., evaluated vaccine regimen), comparators, outcomes, types of vaccine effects evaluated, specific TTE methods, applied statistical methods, and whether the interference was adjusted, incorporated, or discussed. Three reviewers (TK, MW, and KS) independently conducted the full-text screening.

RESULTS

Characteristics, target populations, and data sources of included studies

A total of 234 studies were identified from the database search, and 28 of them met the inclusion criteria after the screening (**Figure 1**).[23–50] Additionally, we identified two studies that did not explicitly state that the TTE approach was used but applied it for vaccine evaluation.[51,52] Therefore, a total of 30 studies were included in the analysis. Most studies were published from 2022 to 2024 (2021: n=2, 7%; 2022: n= 9, 30%; 2023: n= 12, 40%; and 2024: n=7, 23%) (**Table 1**). The United States (n= 14, 47%)[24,27–29,32,38–40,44,45,47,48,50,51] and the United Kingdom (n= 5, 17%)[26,30,36,37,43] were the most common countries represented in the studies. Almost all studies (n=28, 93%) were conducted in high-income countries,[23–33,35–48,50–52] except for two (7%) in upper-middle-income countries.[34,49] Regarding the target population, nine studies (30%) conducted analysis among veterans,[24,27–29,32,38,39,45,47] and one study (3%) was conducted among nursing home residents.[40] Twenty-one studies (70%) conducted analysis among adults aged ≥18 years,[24,26–30,32–34,36–39,41,43–49] three of which (10%) specifically focused on older adults aged ≥60 years.[26,34,43] Four studies (13%) focused on children <18 years.[23,31,35,51] Among studies conducted in the U.S., the most common data source was the national healthcare databases of the Department of Veterans Affairs (n= 9, 64%),[24,27–29,32,38,39,45,47] whereas, in other countries, national healthcare service data, primary care data, cohort data, surveillance data, vaccine registry data, and insurance service data were used. Nationwide healthcare databases were used in 17 studies (57%).[23–25,27–29,32,35,36,38,39,41,42,45–47,49]

Evaluated vaccines, outcomes, and comparators

Almost all studies (n= 27, 90%) evaluated COVID-19 vaccines,[23–34,36–47,49,50,52] with one study each evaluating influenza, MPOX, and rotavirus vaccines.[35,48,51] Among the COVID-19 vaccine studies, 18 (60%) examined the effectiveness against hospitalization and death,[23–25,28–30,32,34,36,38–44,49,52] five (17%) evaluated the effectiveness against infection only,[26,31,37,45,50] one (3%) evaluated the effectiveness against death only,[47] and one (3%) evaluated the effectiveness against infection and death but not for hospitalization.[27] One study (3%) focused on long COVID symptoms,[46] and one study evaluated the safety of COVID-19 vaccines against adverse events.[45] Eleven studies (37%) compared outcomes among vaccinated and unvaccinated individuals,[23,25–27,31,33,34,43,45,47,52] while six studies (20%) compared outcomes among those who received a booster dose and those who did not.[28,38,40,41,44,49] Ten studies (33%) compared outcomes among those who received two different types of COVID-19 vaccines, such as BNT162b2 and mRNA-1273.[24,29,30,32,36,37,39,41,46,49] One study used individuals

who had previous infections as a comparator,[42] and one study evaluated the comparative effectiveness of different dosing intervals.[50]

TTE approaches and statistical methods

Nineteen studies (63%) used a matched cohort,[23,24,26–29,32–36,38,41–43,45,46,49,52] while three studies (10%) used the clone-censor weight analysis to emulate target trials.[47,50,51] One study (3%) prospectively collected observational data to conduct TTE analysis.[37] Various statistical methods were used to quantify and compare vaccine effectiveness and safety across comparators. The majority (n= 21, 70%) used the Kaplan-Meier estimator, Cox proportional hazards model, or both.[23–32,34,37,38,41–45,49,50,52] Seven studies (23%) applied the cumulative incidence function, the Fine-Gray subdistribution hazards model, or both to explicitly account for competing risks.[30,38–40,44,47,51] Three studies (10%) used Poisson regression.[35,36,46] Five studies (17%) applied a causal survival analysis framework to evaluate vaccine effectiveness.[33,40,47,48,51]

Evaluated types of vaccine effects and interference

Among the included studies, three studies (10%) defined the type of vaccine effect that they evaluated, two of which were direct effects[50,51] and one was an overall effect.[23] We did not find any study that explicitly incorporated indirect effects in vaccine evaluation. Only three studies (10%) mentioned the lack of adjustment for interference as a limitation.[40,50,51]

DISCUSSION

Our review showed that TTE approaches have increasingly become a popular method for vaccine evaluation in recent years, particularly following the introduction of COVID-19 vaccines. The majority of the included studies focused on the evaluation of COVID-19 vaccines, but TTE started to be applied to other vaccines, such as rotavirus vaccines, influenza vaccines, and MPOX vaccines. Many studies did not specify which type of vaccine effects – direct, indirect, total, or overall effect – they evaluated. Interference of infectious diseases was not incorporated or addressed in vaccine evaluation in the included studies.

TTE approaches prove useful to evaluate the comparative effectiveness and safety of different vaccines (e.g., BNT162b2 and mRNA-1273 for COVID-19) or various dosing schedules (e.g., single dose vs. two doses of rotavirus vaccines; with vs. without a booster dose of COVID-19 vaccines), using observational data. RCTs cannot practically evaluate the full spectrum of dosing schedules (combination of a total number of doses and timing of each dose) in fine scale due to resource constraints. Real-world observational data, in contrast, have great variations in actual dosing schedules followed by vaccine recipients, which could be used in TTE approaches for evaluation. Selection bias and immortal time bias are major concerns when using observational data for intervention evaluation, as observational studies inherently assume that individuals successfully completed their assigned protocols, with no dropouts or outcomes during the course of intervention. This assumption is frequently violated when evaluating vaccines, especially for those requiring multiple doses, because vaccine schedules themselves affect the completion rate of the schedules. For example, the completion rate would be lower for schedules with a larger number of doses (e.g., with vs. without booster dose). Clone-censor

weight analysis was specifically designed to address these issues by aligning the beginning of the follow-up time period with the date when individuals became eligible for and assigned to each protocol, rather than the date when they completed each protocol.[53] These modern techniques are a promising tool to evaluate the impact of vaccines, especially when RCTs are not feasible or suitable.

Many of the included studies evaluated vaccines among the general population. This is a significant advantage of TTE approaches compared to RCTs that generally focus on smaller populations in selected settings. However, global disparity remained in the TTE studies. Most studies in our scoping review were from the U.S. and Europe. Since the impact of vaccines can vary across different settings due to varying population characteristics, disease burden, and transmission levels, data from diverse populations and regions are critical to guide vaccine policy. TTE could be an affordable tool to achieve this if countries have surveillance databases and vaccine registry databases.[3] To facilitate the use of TTE, it is important to teach these methods in workshops or include them in public health training curricula worldwide.

Despite various advantages of TTE, challenges persist in the application of TTE to vaccine evaluation, particularly concerning interference. The stable unit treatment value assumption (SUTVA) is violated in studies of vaccines,[54,55] because vaccines reduce population-level transmission, subsequently lowering the risk of infection among both vaccinated and unvaccinated individuals (i.e., indirect effect). Different numbers and timing of vaccine doses may produce varying levels of indirect effects, making it crucial to incorporate these effects into vaccine evaluation to identify optimal vaccine strategies. None of the studies in our scoping review addressed or incorporated interference in their vaccine evaluation, although a few mentioned it as a limitation. A few studies specified the types of vaccine effects evaluated, which were either the direct effect or the overall effect. Addressing interference may require alternative approaches, such as agent-based modeling or other types of simulation modeling. For example, agent-based modeling has been used to investigate the causal effects of preexposure prophylaxis among men who have sex with men in the presence of interference or spillover.[56,57] The issue of interference is not restricted to infectious disease research; it is also relevant in fields such as health promotion programs, social epidemiology, mental health, and drug use disorder.[58–62] Further work is needed to explore methods that integrate simulation modeling and target trial emulation framework to address interference in various contexts.

The reliance on conventional survival analysis methods like Kaplan-Meier curves and Cox proportional hazards models in TTE studies raises concerns regarding potential biases, especially concerning competing risks.[63] This is of particular concern when using surveillance data in which studies generally assume that if individuals do not show up in surveillance databases they did not have an outcome. To enhance the robustness of vaccine evaluation, we advocate for the adoption of causal survival analysis frameworks, such as pooled logistic regression with inverse probability weighting, which mitigate bias in long-term follow-up settings.[64] Novel measures like restricted mean survival time (RMST) offer alternatives to evaluate vaccine effectiveness on an absolute scale, complementing traditional hazard ratio estimations.[65]

In summary, TTE has various practical and methodological advantages and is a useful approach for evaluating vaccine programs, especially when RCTs are not feasible. Clone-censor weight analysis is particularly effective for evaluating multi-dose vaccines to avoid selection bias and immortal time bias. Challenges related to interference need to be addressed to incorporate indirect effects or spillover effects in the evaluation of interventions, including vaccines. Moving forward, further collaboration between causal inference researchers and infectious disease experts will be beneficial for developing new approaches and guidelines on the application of TTE for vaccine evaluation in the presence of interference.

ACKNOWLEDGEMENT

We thank Kristen Sheridan for her support with the literature review. This study was also made possible by cooperative agreement CDC-RFA-FT-23-0069 from the CDC's Center for Forecasting and Outbreak Analytics. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

CONFLICT OF INTEREST

The authors have declared no competing interest.

REFERENCES

1. Hernán MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal Inference From Observational Data. *JAMA*. 2022;328(24):2446. doi:10.1001/jama.2022.21383
2. Deaton A, Cartwright N. Understanding and misunderstanding randomized controlled trials. *Soc Sci Med*. 2018;210:2-21. doi:10.1016/j.socscimed.2017.12.005
3. Nsanzimana S, Gupta A, Uwizihiwe JP, et al. The Need for a Practical Approach to Evaluate the Effectiveness of COVID-19 Vaccines for Low- and Middle-Income Countries. *Am J Trop Med Hyg*. 2021;105(3):561-563. doi:10.4269/ajtmh.21-0482
4. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med*. 2021;384(20):1885-1898. doi:10.1056/NEJMoa2102214
5. Equity must be baked into randomized controlled trials. *Nature*. 2022;606(7915):624-624. doi:10.1038/d41586-022-01675-2
6. Habibzadeh F. Disparity in the selection of patients in clinical trials. *The Lancet*. 2022;399(10329):1048. doi:10.1016/S0140-6736(22)00176-3
7. Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1. *Am J Epidemiol*. 2016;183(8):758-764. doi:10.1093/aje/kwv254
8. García-Albéniz X, Hsu J, Hernán MA. The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening. *Eur J Epidemiol*. 2017;32(6):495-500. doi:10.1007/s10654-017-0287-2
9. Caniglia EC, Zash R, Jacobson DL, et al. Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes. *AIDS*. 2018;32(1):113-120. doi:10.1097/QAD.0000000000001673
10. Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. *J Clin Epidemiol*. 2016;79:70-75. doi:10.1016/j.jclinepi.2016.04.014
11. Danaei G, García Rodríguez LA, Cantero OF, Logan RW, Hernán MA. Electronic medical records can be used to emulate target trials of sustained treatment strategies. *J Clin Epidemiol*. 2018;96:12-22. doi:10.1016/j.jclinepi.2017.11.021
12. Antihyperglycemic Therapy and Cardiovascular Risk: Design and Emulation of a Target Trial Using Healthcare Databases. In: ; 2019. https://api.semanticscholar.org/CorpusID:210926774
13. Fernainy P, Cohen AA, Murray E, Losina E, Lamontagne F, Sourial N. Rethinking the pros and cons of randomized controlled trials and observational studies in the era of big data and advanced methods: a panel discussion. *BMC Proc*. 2024;18(S2):1. doi:10.1186/s12919-023-00285-8
14. Cox DR. *Planning of Experiments*. Wiley Classics Libr. ed. Wiley; 1992.
15. Rubin DB. Discussion of “Randomization Analysis of Experimental Data in the Fisher Randomization Test. *J Am Stat Assoc*. 1980;75:591-593. by D. Basu.
16. Hudgens MG, Halloran ME. Toward Causal Inference With Interference. *J Am Stat Assoc*. 2008;103(482):832-842. doi:10.1198/016214508000000292
17. Halloran ME, Struchiner CJ. Causal Inference in Infectious Diseases: *Epidemiology*. 1995;6(2):142-151. doi:10.1097/00001648-199503000-00010
18. Halloran ME, Struchiner CJ. Study Designs for Dependent Happenings: *Epidemiology*. 1991;2(5):331-338. doi:10.1097/00001648-199109000-00004
19. Halloran ME, Longini IM, Struchiner CJ. *Design and Analysis of Vaccine Studies*. Springer; 2010.
20. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018;169(7):467-473. doi:10.7326/M18-0850
21. OSF. Accessed July 3, 2024. https://osf.io/m6b9a
22. Hansford HJ, Cashin AG, Jones MD, et al. Reporting of Observational Studies Explicitly

Aiming to Emulate Randomized Trials: A Systematic Review. *JAMA Netw Open*. 2023;6(9):e2336023. doi:10.1001/jamanetworkopen.2023.36023
23. Chemaitelly H, AlMukdad S, Ayoub HH, et al. Covid-19 Vaccine Protection among Children and Adolescents in Qatar. *N Engl J Med*. 2022;387(20):1865-1876. doi:10.1056/NEJMoa2210058
24. Dickerman BA, Gerlovin H, Madenci AL, et al. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans. *N Engl J Med*. 2022;386(2):105-115. doi:10.1056/NEJMoa2115463
25. Gazit S, Shlezinger R, Perez G, et al. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study. *Ann Intern Med*. 2022;175(5):674-681. doi:10.7326/M21-4130
26. Català M, Burn E, Rathod-Mistry T, et al. Observational methods for COVID-19 vaccine effectiveness research: an empirical evaluation and target trial emulation. *Int J Epidemiol*. 2024;53(1). doi:10.1093/ije/dyad138
27. Ioannou GN, Locke ER, O'Hare AM, et al. COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System : A Target Trial Emulation Study. *Ann Intern Med*. 2022;175(3):352-361. doi:10.7326/M21-3256
28. Ioannou GN, Bohnert ASB, O'Hare AM, et al. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era. *Ann Intern Med*. 2022;175(12):1693-1706. doi:10.7326/M22-1856
29. Ioannou GN, Locke ER, Green PK, Berry K. Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system. *EClinicalMedicine*. 2022;45:101326. doi:10.1016/j.eclinm.2022.101326
30. Wei J, Zhang W, Doherty M, et al. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19. *BMC Med*. 2023;21(1):78. doi:10.1186/s12916-023-02795-w
31. Gazit S, Saciuk Y, Perez G, et al. Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation. *Lancet Microbe*. 2023;4(7):e495-e505. doi:10.1016/S2666-5247(23)00103-9
32. Dickerman BA, Gerlovin H, Madenci AL, et al. Comparative effectiveness of third doses of mRNA-based COVID-19 vaccines in US veterans. *Nat Microbiol*. 2023;8(1):55-63. doi:10.1038/s41564-022-01272-z
33. Tran VT, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort. *BMJ Med*. 2023;2(1):e000229. doi:10.1136/bmjmed-2022-000229
34. Monteiro HS, Lima Neto AS, Kahn R, et al. Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study. *Vaccine*. 2023;41(39):5742-5751. doi:10.1016/j.vaccine.2023.07.065
35. Kildegaard H, Lund LC, Pottegård A, Stensballe LG. Effectiveness of the quadrivalent live attenuated influenza vaccine against influenza-related hospitalisations and morbidity among children aged 2 to 6 years in Denmark: a nationwide cohort study emulating a target trial. *Lancet Child Adolesc Health*. 2023;7(12):852-862. doi:10.1016/S2352-4642(23)00225-0
36. Kerr S, Bedston S, Bradley DT, et al. Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales. *Int J Epidemiol*. 2023;52(1):22-31. doi:10.1093/ije/dyac199
37. Nguyen VG, Yavlinsky A, Beale S, et al. Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort. *Int J Epidemiol*. 2023;52(2):342-354. doi:10.1093/ije/dyad002

38. Butt AA, Talisa VB, Shaikh OS, Omer SB, Mayr FB. Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2022;75(12):2161-2168. doi:10.1093/cid/ciac328
39. Kelly JD, Leonard S, Boscardin WJ, et al. Comparative mRNA booster effectiveness against death or hospitalization with COVID-19 pneumonia across at-risk US Veteran populations. *Nat Commun*. 2023;14(1):2976. doi:10.1038/s41467-023-38503-8
40. McConeghy KW, Bardenheier B, Huang AW, et al. Infections, Hospitalizations, and Deaths Among US Nursing Home Residents With vs Without a SARS-CoV-2 Vaccine Booster. *JAMA Netw Open*. 2022;5(12):e2245417. doi:10.1001/jamanetworkopen.2022.45417
41. Andersson NW, Thiesson EM, Baum U, et al. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study. *BMJ*. 2023;382:e075286. doi:10.1136/bmj-2022-075286
42. Chemaitelly H, Ayoub HH, AlMukdad S, et al. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. *Lancet Microbe*. 2022;3(12):e944-e955. doi:10.1016/S2666-5247(22)00287-7
43. Hulme WJ, Williamson E, Horne EMF, et al. Challenges in Estimating the Effectiveness of COVID-19 Vaccination Using Observational Data. *Ann Intern Med*. 2023;176(5):685-693. doi:10.7326/M21-4269
44. Hanberg JS, Fu X, Wang X, et al. Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial. *Lancet Rheumatol*. 2024;6(1):e21-e30. doi:10.1016/S2665-9913(23)00272-2
45. Li G, Gerlovin H, Figueroa Muñiz MJ, et al. Comparison of the Test-negative Design and Cohort Design With Explicit Target Trial Emulation for Evaluating COVID-19 Vaccine Effectiveness. *Epidemiol Camb Mass*. 2024;35(2):137-149. doi:10.1097/EDE.0000000000001709
46. Choi MJ, Na Y, Hyun HJ, et al. Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2024;30(5):646-652. doi:10.1016/j.cmi.2023.12.010
47. McConeghy KW, Hur K, Dahabreh IJ, et al. Early Mortality After the First Dose of COVID-19 Vaccination: A Target Trial Emulation. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2024;78(3):625-632. doi:10.1093/cid/ciad604
48. Rosen JB, Arciuolo RJ, Pathela P, et al. JYNNEOS™ effectiveness as post-exposure prophylaxis against mpox: Challenges using real-world outbreak data. *Vaccine*. 2024;42(3):548-555. doi:10.1016/j.vaccine.2023.12.066
49. Lazar Neto F, Hitchings MDT, Amin AB, et al. Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study. *Lancet Reg Health Am*. 2024;34:100755. doi:10.1016/j.lana.2024.100755
50. Shioda K, Breskin A, Harati P, et al. Comparative effectiveness of alternative intervals between first and second doses of the mRNA COVID-19 vaccines. *Nat Commun*. 2024;15(1):1214. doi:10.1038/s41467-024-45334-8
51. Butler AM, Breskin A, Sahrmann JM, Brookhart MA. Estimating the Effectiveness of Rotavirus Vaccine Schedules. *Epidemiology*. 2021;32(4):598-606. doi:10.1097/EDE.0000000000001363
52. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med*. 2021;384(15):1412-1423. doi:10.1056/NEJMoa2101765
53. Gaber CE, Hanson KA, Kim S, Lund JL, Lee TA, Murray EJ. The Clone-Censor-Weight Method in Pharmacoepidemiologic Research: Foundations and Methodological Implementation. *Curr Epidemiol Rep*. Published online February 17, 2024. doi:10.1007/s40471-024-00346-2

54. Robins J. A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect. *Math Model*. 1986;7(9-12):1393-1512. doi:10.1016/0270-0255(86)90088-6
55. Rubin DB. Randomization Analysis of Experimental Data: The Fisher Randomization Test Comment. *J Am Stat Assoc*. 1980;75(371):591. doi:10.2307/2287653
56. Murray EJ, Marshall BDL, Buchanan AL. Emulating Target Trials to Improve Causal Inference From Agent-Based Models. *Am J Epidemiol*. 2021;190(8):1652-1658. doi:10.1093/aje/kwab040
57. Buchanan AL, Bessey S, Goedel WC, et al. Disseminated Effects in Agent-Based Models: A Potential Outcomes Framework and Application to Inform Preexposure Prophylaxis Coverage Levels for HIV Prevention. *Am J Epidemiol*. 2021;190(5):939-948. doi:10.1093/aje/kwaa239
58. Morozova O, Crawford FW, Cohen T, Paltiel AD, Altice FL. Cost‐effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. *Addiction*. 2020;115(3):437-450. doi:10.1111/add.14797
59. Komura T, Tsugawa Y, Kondo N, Inoue K. Depression Onset After a Spouse's Cardiovascular Event. *JAMA Netw Open*. 2024;7(4):e244602. doi:10.1001/jamanetworkopen.2024.4602
60. Tracy M, Cerdá M, Keyes KM. Agent-Based Modeling in Public Health: Current Applications and Future Directions. *Annu Rev Public Health*. 2018;39(1):77-94. doi:10.1146/annurev-publhealth-040617-014317
61. Cerdá M, Keyes KM. Systems Modeling to Advance the Promise of Data Science in Epidemiology. *Am J Epidemiol*. 2019;188(5):862-865. doi:10.1093/aje/kwy262
62. Steeves S, Acciai F, Tasevska N, DeWeese RS, Yedidia MJ, Ohri-Vachaspati P. The Special Supplemental Nutrition Program for Women, Infants, and Children Spillover Effect: Do Siblings Reap the Benefits? *J Acad Nutr Diet*. 2020;120(8):1288-1294. doi:10.1016/j.jand.2020.02.013
63. Coemans M, Verbeke G, Döhler B, Süsal C, Naesens M. Bias by censoring for competing events in survival analysis. *BMJ*. Published online September 13, 2022:e071349. doi:10.1136/bmj-2022-071349
64. Murray EJ, Caniglia EC, Petito LC. Causal survival analysis: A guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence. *Res Methods Med Health Sci*. 2021;2(1):39-49. doi:10.1177/2632084320961043
65. Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. *BMC Med Res Methodol*. 2013;13(1):152. doi:10.1186/1471-2288-13-152

FIGURES

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 flow diagram for the systematic review.



TABLES

Table 1. Characteristics of included studies.

Researchers	Target population	Country	Data source	Evaluated vaccine and schedule	Comparator	Outcome	Evaluated type of vaccine effect	Specific target trial emulation method	Statistical method	Year
Chemaitelly, *et al.*	37,456 children between 5 to 11 years of age and adolescents between 12 to 17 years of age	Qatar	National databases for vaccination, SARS-CoV-2 testing, and hospitalization and death	BNT162b2 (first dose)	Unvaccinated	SARS-CoV-2 infection hospitalization, and death	Overall effect	Matched retrospective cohort (1:1)	Kaplan–Meier estimator and Cox proportional hazards model	2022
Dickerman, *et al.*	219,842 veterans aged ≥18 years	US	National healthcare databases of the Department of Veterans Affairs	BNT162b2 (first dose)	mRNA-1273 (first dose)	SARS-CoV-2 infection hospitalization, and death	Not specified	Matched cohort (1:1)	Kaplan–Meier estimator	2022
Gazit, *et al.*	2,044,257 individuals aged ≥16 years and previously infected to SARS-CoV-2	Israel	National database of Maccabi Healthcare Services	BNT162b2 (first dose)	Unvaccinated	SARS-CoV-2 infection, hospitalization, and death	Not specified	Retrospective cohort	Cox proportional hazards model	2022

Català, *et al.*	459,000 individuals aged ≥75	UK	Primary care data from the Clinical Practice Research Datalink AURUM	BNT162b2 or ChAdOx1 (first dose)	Unvaccinated	SARS-CoV-2 infection	Not specified	Matched cohort	Kaplan–Meier estimator and Cox proportional hazards model	2023
Ioannou, *et al.*	4,199,742 individuals aged ≥18 receiving care in the Veterans Affairs health care system	US	National healthcare databases of the Department of Veterans Affairs	mRNA COVID-19 vaccines (first dose)	Unvaccinated	SARS-CoV-2 infection and death	Not specified	Matched cohort (1:1)	Kaplan–Meier estimator and Cox proportional hazards model	2022
Ioannou, *et al.*	490,838 individuals aged ≥18 receiving care in the Veterans Affairs health care system	US	National healthcare databases of the Department of Veterans Affairs	Booster monovalent mRNA vaccination (BNT162b2 or mRNA-1273)	Not receiving the booster	SARS-CoV-2 infection, hospitalization, and death	Not specified	Retrospective matched cohort (1:1)	Kaplan–Meier estimator and Cox proportional hazards model	2022
Ioannou, *et al.*	902,235 individuals aged ≥18 receiving care in the Veterans Affairs health care system	US	National healthcare databases of the Department of Veterans Affairs	BNT162b2 (first dose)	mRNA-1273 (first dose)	SARS-CoV-2 infection, hospitalization, and death	Not specified	Retrospective matched cohort (1:1)	Kaplan–Meier estimator and Cox proportional hazards model	2022
Wei, *et al.*	1,311,075 individuals aged ≥18 from the IQVIA Medical Research Database (IMRD)	UK	IQVIA Medical Research Database	BNT162b2 (first dose)	ChAdOx1 nCoV-19 (first dose)	SARS-CoV-2 infection, hospitalization, and death	Not specified	Cohort	Cumulative incidence curves and Cox proportional hazards model	2023

Gazit, *et al.*	780,148 children between 5 to 11 years of age and adolescents between 12 to 16 years of age	Israel	The Maccabi Healthcare Services	BNT162b2 (first dose)	Unvaccinated	SARS-CoV-2 infection	Not specified	Retrospective cohort	Cox proportional hazards model	2023
Dickerman, *et al.*	130,392 veterans aged ≥18 years	US	National healthcare databases of the Department of Veterans Affairs	BNT162b2 (third dose)	mRNA-1273 (third dose)	SARS-CoV-2 infection, hospitalization, and death	Not specified	Matched cohort (1:1)	Kaplan–Meier estimator	2023
Tran, *et al.*	910 adult patients aged ≥18 years	France	The ComPaRe long covid cohort	BNT162b2 (first dose)	Unvaccinated	Long COVID symptoms	Not specified	Matched cohort (1:1)	Multivariable logistic regression model	2023
Monteiro, *et al.*	125,286 adults aged ≥60 years	Brazil	INTEGRASUS (a surveillance tool by the State Health Department) and VACINE JÁ (a COVID-19 vaccination database)	CoronaVac (first dose)	Unvaccinated	SARS-CoV-2 infection, hospitalization, and death	Not specified	Retrospective matched cohort (1:1)	Kaplan–Meier estimator	2023
Kildegaard, *et al.*	308,520 children aged 2–6 years	Denmark	Nationwide Danish health-care registries and databases	Live attenuated influenza vaccines (LAIV-4)	Unvaccinated	Any hospital contact for influenza and influenza-related hospital admissions	Not specified	Matched cohort (1:1)	Poisson regression model	2023

Kerr, *et al.*	4,566,696 adults aged ≥18 years	UK	Linkage across 28 National databases across UK nations	ChAdOx1 (first/second dose)	BNT162b2 (first/second dose)	SARS-CoV-2 infection, hospitalization, and death	Not specified	Matched cohort (1:1)	Poisson regression model	2023
Nguyen, *et al.*	19,159 adults aged ≥18 years who received booster vaccination	UK	The Virus Watch cohort	ChAdOx1 (primary courses)	BNT162b2 (primary courses)	SARS-CoV-2 infection	Not specified	Prospective cohort	Kaplan–Meier estimator and Cox proportional hazards model	2023
Butt, *et al.*	925,900 veterans ≥21 years	US	National health care databases of the Department of Veterans Affairs	BNT162b2 or mRNA-1273 (booster)	Not receiving the booster	SARS-CoV-2 infection, hospitalization, and death	Not specified	Retrospective matched cohort (1:1)	Cumulative incidence curves and Cox proportional hazards model	2022
Kelly, *et al.*	1,703,189 veterans aged ≥18 years	US	National health care databases of the Department of Veterans Affairs	Three doses of mRNA-1273	Three doses of BNT162b2	SARS-CoV-2 infection, hospitalization, and death	Not specified	Cohort	Cumulative incidence function and Fine-Gray model	2023
McConeghy, *et al.*	10,949 nursing home residents	US	Databases of Genesis HealthCare and Veterans Health Administration community living centers	Receiving a SARS-CoV-2 mRNA booster	Not receiving the booster	SARS-CoV-2 infection, hospitalization, and death	Not specified	Cohort	Cumulative incidence curves and pooled logistic regression model	2022

Andersson, *et al.*	4,333,174 individuals aged ≥50 years	Denmark, Finland, Norway, and Sweden	Nationwide demography and healthcare registers	A: Receiving a fourth dose B: Bivalent BA.4-5 mRNA booster (fourth dose)	A: Not receiving the fourth dose B: Bivalent BA.1 mRNA booster (fourth dose)	SARS-CoV-2 infection, hospitalization, and death	Not specified	Matched cohort (1:1)	Kaplan–Meier estimator	2023
Chemaitelly, *et al.*	209,000 individuals	Qatar	National databases for vaccination, SARS-CoV-2 testing, and hospitalization and death	Two doses of same vaccine (BNT162b2 or mRNA-1273)	Natural infection	SARS-CoV-2 infection, hospitalization, and death	Not specified	Matched cohort (1:1)	Kaplan–Meier estimator and Cox proportional hazards model	2022
Hulme, *et al.*	2,780,931 individuals aged ≥70 years	UK	Primary care records, linked with hospital, death registry, vaccination, and surveillance database	BNT162b2 or ChAdOx1 (first dose)	Unvaccinated	SARS-CoV-2 infection, hospitalization, and death	Not specified	Matched cohort (1:1)	Kaplan–Meier estimator and Cox proportional hazards model	2023
Hanberg, *et al.*	4,305 patients aged ≥18 years with systemic autoimmune rheumatic diseases	US	The Mass General Brigham health-care system	BNT162b2 or mRNA-1273 (fourth dose)	Not receiving the fourth dose	SARS-CoV-2 infection, hospitalization, and death	Not specified	Cohort	Cox proportional hazards model, cumulative incidence function and Fine-Gray model	2024
Li, *et al.*	1,093,620 veterans aged ≥18 years	US	National healthcare databases of the Department of Veterans Affairs	BNT162b2 (first dose)	Unvaccinated	SARS-CoV-2 infection	Not specified	Test-negative design matched cohort (1:1)	Kaplan–Meier estimator	2024

Choi, *et al.*	1,767,539 individuals aged ≥18 years	South Korea	The National Health Insurance Service database	ChAdOx1 (first dose)	BNT162b2 or mRNA-1273 (first dose)	Adverse events of special interest (Incl. acute cardiac injury, myocarditis /pericarditis, arrhythmia, Guillain–Barré syndrome, vasovagal syncope, radiculopathy, and aseptic arthritis)	Not specified	Retrospective matched cohort (1:1)	Poisson regression	2024
McConeghy, *et al.*	3,158,507 veterans aged ≥18	US	National healthcare databases of the Department of Veterans Affairs	mRNA COVID-19 vaccination (first dose)	Unvaccinated	Any cause of death excluding recent SARS-CoV-2 infection	Not specified	Cohort (clone-censor weight analysis)	Cumulative incidence curves	2024
Rosen, *et al.*	594 NYC residents aged ≥18 and having had a high-risk or intermediate-risk exposure to a person with confirmed or probable MPOX disease	US	The New York City Department of Health and Mental Hygiene surveillance database	A single dose of JYNNEOSTM vaccine as post-exposure prophylaxis (PEP)	Not receiving PEP	Development of MPOX	Not specified	Retrospective cohort	Pooled logistic regression	2024

Lazar, *et al.*	53,456,500 individuals aged ≥ 40 who received at least 3 doses of COVID-19 vaccination	Brazil	eSUS, SIVEP-Gripe, the national vaccination database (SI-PNI), and the mortality registry system (SIM)	Cohort A: Receiving a fourth vaccination Cohort B: mRNA-based fourth vaccination	Cohort A: Not receiving fourth vaccination Cohort B: Adenovirus-based fourth vaccination	SARS-CoV-2 associated hospitalization or death	Not specified	Matched cohort (rolling entry matching)	Kaplan-Meyer estimator and Cox proportional hazard models	2024
Shioda, *et al.*	6,128,364 mRNA COVID-19 vaccine recipients	US	The Georgia Department of Public Health vaccine database, the State Electronic Notifiable Disease Surveillance System	Late-but-allowable interdose interval, and late interdose interval	Recommended interdose interval by the FDA	SARS-CoV-2 infection	Direct effect	Cohort (clone-censor weight analysis)	Cox proportional hazard models and cumulative risk curves	2024
Butler, *et al.*	1,147,699 infants with ≥38 days of age	US	IBM® MarketScan® Commercial Database	1 or 2 doses of rotavirus vaccine	Unvaccinated	Acute gastroenteritis-related emergency department visits or hospitalization	Direct effect	Cohort (clone-censor weight analysis)	Cumulative risk function	2021
Dagan, *et al.*	3,159,136 individuals aged ≥ 16	Israel	Clalit Health Services Data	BNT162b2 (first dose)	Unvaccinated	SARS-CoV-2 infection, symptomatic Covid-19, hospitalization, severe illness, and death	Not specified	Matched cohort (1:1)	Kaplan-Meyer estimator	2021

SUPPLEMENTARY MATERIALS

Supplementary Table 1. Search terms and results of the literature review.

Search word	Medium	Start Date	End Date	Result
(("2012/01/01"[Date - Publication] : "2024/5/21"[Date - Publication])) AND (((target trial[Title/Abstract]) OR (target emulation[Title/Abstract]) OR (trial emulation[Title/Abstract]) OR (targeted trial[Title/Abstract]) OR (emulated trial[Title/Abstract]) OR (emulated target[Title/Abstract])) AND ((infectious diseases[Title/Abstract]) OR (infection[Title/Abstract]) OR (vaccine[Title/Abstract]) OR (vaccination[Title/Abstract]) OR (immunization[Title/Abstract])))	PubMed	2012/01/01	2024/05/21	74
(‘target trial':ti,ab OR ‘target emulation':ti,ab OR ‘trial emulation':ti,ab OR ‘targeted trial':ti,ab OR ‘emulated trial':ti,ab OR ‘emulated target':ti,ab) AND (‘infectious diseases':ti,ab OR ‘infection':ti,ab OR ‘vaccine':ti,ab OR ‘vaccination':ti,ab OR ‘immunization':ti,ab)	Embase	2012/01/01	2024/05/21	101
(TI=("target trial" OR "target emulation" OR "trial emulation" OR "targeted trial" OR "emulated trial" OR "emulated target")OR AB=("target trial" OR "target emulation" OR "trial emulation" OR "targeted trial" OR "emulated trial" OR "emulated target")) AND (TI=("infectious diseases" OR "infection" OR "vaccine" OR "vaccination" OR "immunization") OR AB=("infectious diseases" OR "infection" OR "vaccine" OR "vaccination" OR "immunization"))	Web of Science	2012/01/01	2024/05/21	59

*Results as of May 21, 2024